[Edaily Reporter NA EUN-KYUNG ] Celltrion Pharm Inc.(068760)is building a large-scale production facility in North Chungcheong Province to respond to the expansion of the global pre-filled syringe (PFS) market.

Celltrion Pharm Inc. announced a mid- to long-term investment plan on the 2nd through a regulatory filing, stating it will invest a total of 2 trillion won to construct a PFS production facility in North Chungcheong Province.

This investment is intended to meet growing global demand for PFS and expand production capacity. The company plans to complete the first phase of the new production facility between 2028 and 2033, followed by a second-phase investment to construct additional facilities based on future global demand trends.

PFS (Pre-filled Syringe) refers to syringes that are shipped with a predetermined dose of medication already filled. As they enhance the convenience and safety of administration, their adoption is rapidly expanding, particularly for biopharmaceuticals and vaccines. In particular, as the market for self-injectable medications—such as obesity treatments and immunotherapy drugs—grows, global pharmaceutical companies are increasingly adopting PFS. The industry expects demand for PFS to continue growing alongside the expansion of the biopharmaceutical market.

Celltrion Pharm Inc. expects this investment to expand its medium- to long-term global supply capacity and strengthen its production competitiveness.

Celltrion Pharm Inc. already operates production facilities for synthetic and biopharmaceuticals in Cheongju and Jincheon, North Chungcheong Province. If this new PFS production facility is constructed in the North Chungcheong region, it is expected to improve production efficiency and optimize supply chain operations in conjunction with existing production hubs.

However, the company stated that this announcement is intended to explain its mid- to long-term investment plans, and that the investment schedule and scale are subject to change depending on future market conditions and the company’s business environment.